Page results
-
UCLH is a centre of excellence in the management of patients with acute and chronic leukaemia.
-
Myelodysplastic syndrome (MDS), or myelodysplasia, is a blood disorder that causes a drop in your number of healthy blood cells.
-
Our specialist myeloma team holds four myeloma outpatient clinics per week, seeing over 300 patients every month.
-
Myeloproliferative neoplasms (MPN) are disorders that affect how the body produces red blood cells, white blood cells, and platelets.
-
The Preterm Birth Clinic is one of a few UK specialist antenatal services that are designed specifically for the needs of pregnant women at risk of premature labour.
-
How to contact the London Sarcoma Service.
-
UCLH has welcomed its 1000th patient to our proton beam therapy department, which opened in December 2021.
-
Ibrahim Abubakar is Vice Provost (Health) and Professor of Infectious Disease Epidemiology at UCL. He is a member of the Global Preparedness Monitoring Board, University College London NHS Trust Board, UCL Partners Board and the Board of Resolve to Save Lives.
-
“Vaccines do not kill, the virus does”: that was the message from local leaders from a variety of different faiths during an event at the newly opened vaccination centre at the Business Design Centre in Islington.
-
Two directors have joined the UCLH Board – Liz O’Hara, director of workforce and Laura Churchward, director of strategy.
File results
-
FOI/2023/0188 - Payments to suppliers
-
FOI/2023/0202 - Nitrous oxide/ Entonox personal sampling for staff
-
FOI/2023/0203 - Maintenance contract(s) for flexible endoscope inventory
-
FOI/2023/0210 - Top five drugs that expired by value
-
FOI/2023/0211 - Services available to older residents
-
FOI/2023/0212 - Training provided to clinical staff for use of medical devices
-
FOI/2023/0222 - Contact details for senior screening and immunisations staff
-
FOI/2023/0231 - Patients seen at A&E with symptoms of taking nitrous oxide gas
-
FOI/2023/0237 - Software solution to manage patient e-consent for school vaccinations/ immunisations and waitlist validation
-
FOI/2023/0250 - Early Access to Medicines Scheme (EAMS)